Integrated care and treatment for severe infectious diseases and substance use disorders (SUD) among hospitalized patients (CTN-0121). 09/28/2022 - 02/07/2026. DSC6. 75N95022F00002 (TO2).
Active Awarded Last action
- Contract number
- 75N95022F00002
- Awardee
-
The Emmes Company, LLC UEI NBQCBJ6FXBU4
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,067,729
Award facts
- Opportunity
-
- Data, Statistics, and Clinical Trial Support Center (DSC6) Pre-Solicitation · 75N95022F00002 · Posted Nov 10, 2021
- Contract value 100% obligated
- $2,067,729.00 Current and potential, with all options
- Completion date 81% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $667,732 | |
| Original award | $1,399,997 |
About this award
The National Institute on Drug Abuse (NIDA) awarded a Delivery Order (TO2) valued at $2.07M to The Emmes Company, LLC for the Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized Patients (CTN-0121) clinical trial. The contract runs from September 28, 2022 through September 30, 2027 and operates under a Cost Plus Fixed Fee pricing structure with no set-aside designation. This delivery order is issued under NIDA's Data, Statistics, and Clinical Trial Support Center Indefinite Delivery Vehicle, a $31.2M IDV that enables the agency to procure flexible research support services. The work will be performed in Potomac, Maryland.
The Emmes Company, LLC, a clinical research organization headquartered in Rockville, Maryland, specializes in providing comprehensive biostatistical analysis, data management, clinical trial coordination, and regulatory support services to the National Institutes of Health. CTN-0121 represents part of NIDA's Clinical Trials Network and focuses on developing and testing integrated treatment approaches for individuals with both severe infectious diseases and substance use disorders in hospital settings. As a specialized clinical research contractor with extensive experience managing complex federal research initiatives across multiple NIH institutes, Emmes is well-positioned to provide the data coordination center and clinical trial support services required for this multi-year initiative addressing a critical gap in integrated medical and behavioral health treatment.
Quick answers
Who was awarded contract 75N95022F00002?
75N95022F00002 was awarded to The Emmes Company, LLC by National Institute on Drug Abuse (National Institutes of Health) on September 28, 2022.
How much is contract 75N95022F00002 worth?
The government has obligated $2,067,729 on 75N95022F00002.
Is contract 75N95022F00002 an order under another contract?
Yes. 75N95022F00002 is a delivery order under 75N95022D00017, an indefinite delivery contract.
Was contract 75N95022F00002 competed?
The extent of competition for 75N95022F00002 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award